Stability of sunitinib in oral suspension

Annals of Pharmacotherapy

Volumn 42, Issue 7-8, 2008, Pages 962-966

  Navid, Fariba ^a,b   Christensen, Robbin ^a   Minkin, Patton ^a   Stewart, Clinton F ^a   Furman, Wayne L ^a,b   Baker, Sharyn ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Oral solution; Stability; Sunitinib

Indexed keywords

ACETONITRILE; CLOZAPINE; DRUG CARRIER; ORA PLUS SOLUTION; ORA SWEET SOLUTION; SUNITINIB;

ARTICLE; CONCENTRATION (PARAMETERS); DILUTION; DRUG CAPSULE; DRUG FORMULATION; DRUG MIXTURE; DRUG SOLUTION; DRUG STABILITY; FREEZING; LIQUID; LIQUID CHROMATOGRAPHY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; ROOM TEMPERATURE; SAMPLING; SUSPENSION; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DRUG COMPOUNDING; DRUG STABILITY; DRUG STORAGE; INDOLES; PYRROLES; REFRIGERATION; SUSPENSIONS;

EID: 48249087244     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K654     Document Type: Article

References (20)

1. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
2. Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13:1367-73.
3. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003;2:1011-21.
4. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-93.
5. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
6. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
7. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24.
8. Houk BE, Amantea M, Motzer RJ, et al. Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC) (abstract 4531). ASCO Annu Meeting Proc Part 12006;24:224s.
9. Prescribing information. Sutent (sunitinib malate). New York: Pfizer Inc., March 2006.
10. Sistla A, Sunga A, Phung K, Koparkar A, Shenoy N. Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trials. Drug Dev Ind Pharm 2004;30:19-25.
11. Guidence for industry bioanalytical method validation. www.fda.gov/cder/guidance/4252fnl.htm (accessed 2008 Jun 15).
12. Abdel-Rahman SM, Reed MD, Wells TG, Kearns GL. Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls. Clin Pharmacol Ther 2007;81:483-94.
13. Balakrishnan K, Grieve J, Tordoff J, Norris P, Reith D. Pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002. J Clin Pharmacol 2006;46:1038-43.
14. Allen LV Jr, Erickson MA. Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids. Am J Health Syst Pharm 1998;55:1804-9.
15. Allen LV Jr, Erickson MA 3rd. Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids. Am J Health Syst Pharm 1998;55:1915-20.
16. Caruthers RL, Johnson CE. Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions. Am J Health Syst Pharm 2007;64:1513-5.
17. Nahata MC, Morosco RS, Trowbridge JM. Stability of dapsone in two oral liquid dosage forms. Ann Pharmacother 2000;34:848-50. DOI 10.1345/aph.19273
18. Nahata MC, Morosco RS, Willhite EA. Stability of nifedipine in two oral suspensions stored at two temperatures. J Am Pharm Assoc (Wash) 2002;42:865-7.
19. Pawar S, Kumar A. Issues in the formulation of drugs for oral use in children: role of excipients. Paediatr Drugs 2002;4:371-9.
20. European medicines agency. Sutent scientific discussion. www.emea.europa.eu/humandocs/PDFs/EPAR/sutent/068706en6.pdf (accessed 2008 Jun 15).